Indivior Welcomes White House Announcement Prioritizing Expanded Access to Evidence-Based Treatment

U.S. Office of National Drug Control Policy sets out seven priorities to address the overdose and addiction epidemic

Richmond, VA April 21, 2021- Indivior PLC (LON: INDV) welcomes the announcement from the U.S. Office of National Drug Control Policy (ONDCP) regarding the Biden-Harris Administration’s drug policy priorities for its first year in office. According to ONDCP, these important priorities range from expanding access to prevention, treatment, recovery, and harm reduction services, reducing the supply of illicit substances, and addressing racial equity in drug policy and health care.

“We are encouraged by the announcement from the White House outlining clear priorities for this Administration to help address the drug overdose and addiction epidemic, including prioritizing expanded access to evidence-based treatment options for people struggling with substance use disorder,” said Mark Crossley, Chief Executive Officer, Indivior. “More than 87,000 people have died from drug overdose deaths during the COVID-19 pandemic, underscoring the urgent need for an integrated and comprehensive approach.2 Tragically, about nine in ten suffering from substance use disorder – our family, friends, and neighbors – are not receiving any treatment.

“We must destigmatize substance use disorder and continue to build awareness that this disease can and must be treated like other chronic diseases,” Crossley said. “We also commend the Administration’s focus on treatment equity for all, including in communities of color and across the criminal justice system. We look forward to working with the Administration and policymakers in Washington D.C. to expand access to all evidence-based treatment options at this time of unprecedented urgency.”

About Indivior

Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.

Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
 

Investor Contact:
Jason Thompson,
Indivior Vice President,
Investor Relations
+1 804-402-7123
Jason.Thompson@indivior.com
 

Media Contacts:

UK:
Tulchan Communications
+44 207-353-4200
 

US:
IndiviorMediaContacts@indivior.com
+1 804-594-0836